Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Blood

Volumn 123, Issue 20, 2014, Pages 3073-3079

  Martinez Lopez, Joaquin ^a   Lahuerta, Juan J ^a   Pepin, François ^b   González, Marcos ^c   Barrio, Santiago ^a   Ayala, Rosa ^a   Puig, Noemí ^c   Montalban, María A ^a   Paiva, Bruno ^d   Weng, Li ^b   Jiménez, Cristina ^c   Sopena, María ^a   Moorhead, Martin ^b   Cedena, Teresa ^a   Rapado, Immaculada ^a   Victoria Mateos, María ^c   Rosiñol, Laura ^e   Oriol, Albert ^f   Blanchard, María J ^g   Martínez, Rafael ^h   Bladé, Joan ^e   Miguel, Jesús San ^d   Faham, Malek ^b   García Sanz, Ramón ^c   more..

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Sequenta Inc   (United States)

^c CSIC   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE REARRANGEMENT; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; COHORT STUDIES; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 84901411165     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-550020     Document Type: Article

References (50)

1. Corso A, Nozza A, Lazzarino M, et al. Plateau phase in multiple myeloma: an end-point of conventional-dose chemotherapy. Haematologica. 1999;84(4):336-341. (Pubitemid 29474348)
2. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998;16(12): 3832-3842.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
4. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298-1301. (Pubitemid 16080597)
5. Bladé J, Samson D, Reece D, et al; Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123. (Pubitemid 28435189)
6. Martinez-Lopez J, Blade J, Mateos MV, et al; Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood. 2011;118(3):529-534.
7. Hajek R, Okubote SA, Svachova H. Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma. Br J Haematol. 2013;163(5): 551-564.
8. Brüggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL? Blood. 2012;120(23):4470-4481.
9. Ho TC, Becker MW. Defining patient-specific risk in acute myeloid leukemia. J Clin Oncol. 2013; 31(31):3857-3859.
10. Paiva B, Vidriales MB, Cerveró J, et al; GEM (Grupo Españ ol de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Groups. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10): 4017-4023.
11. Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540-2547.
12. Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol. 2000; 18(11):2273-2281. (Pubitemid 30350220)
13. Martinez-Lopez J, Fernández-Redondo E, García-Sánz R, et al; GEM (Grupo Españ ol Multidisciplinar de Melanoma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Clinical applicability and prognostic significance of molecular response assessed by fluorescent- PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol. 2013;163(5):581-589.
14. Mitterer M, Oduncu F, Lanthaler AJ, et al. The relationship between monoclonal myeloma precursor B cells in the peripheral blood stem cell harvests and the clinical response of multiple myeloma patients. Br J Haematol. 1999;106(3): 737-743. (Pubitemid 29434216)
15. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-397.
16. Martínez-Sánchez P, Montejano L, Sarasquete ME, et al. Evaluation of minimal residual disease in multiple myeloma patients by fluorescentpolymerase chain reaction: the prognostic impact of achieving molecular response. Br J Haematol. 2008;142(5):766-774.
17. Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011;29(12):1627-1633.
18. Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013;163(1):123-126.
19. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2012;120(26):5173-5180.
20. Gawad C, Pepin F, Carlton VE, et al. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012;120(22): 4407-4417.
21. Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27(8): 1659-1665.
22. Vij R, Mazumder A, Klinger M, et al. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2014;14(2): 131-139.
23. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol. 2008;26(35):5775-5782.
24. Mateos MV, Oriol A, Martínez-López J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-941.
25. Rosiñ ol L, Oriol A, Teruel AI, et al; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Españ ol de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8): 1589-1596.
26. Mateos MV, Martínez-López J, Hernandez MT, et al. Comparison of sequential vs. alternating administration of bortezomib, melphalan and prednisone and lenalidomide plus dexamethasone in elderly patients with newly diagnosed multiple myeloma patients: GEM2010mas65 Trial. Blood. 2013;122:403. [ASH Annual Meeting Abstracts].
27. Paiva B, Vidriales MB, Montalban MA, et al. Analysis of immunophenotypic response by multiparameter flow cytometry in 516 myeloma patients included in three consecutive Spanish trials. Blood. 2010;116:1910. [ASH Annual Meeting Abstracts].
28. Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1 Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Blood. 2011;117(18):4691-4695.
29. Paiva B, Gutiérrez NC, Rosiñ ol L, et al; PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study Groups. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687-691.
30. Sarasquete ME, García-Sanz R, González D, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelicspecific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica. 2005;90(10):1365-1372. (Pubitemid 41503652)
31. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135-143.
32. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
33. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res. 2011;17(6):1225-1233.
34. Attal M, Lauwers-Cances V, Marit G, et al; IFM Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
35. Badros AZ. Lenalidomide in myeloma - a highmaintenance friend. N Engl J Med. 2012;366(19): 1836-1838.
36. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19): 1770-1781.
37. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-1769.
38. Munshi NC, Anderson KC. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013; 31(20):2523-2526.
39. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12): 2077-2084.
40. Bakkus MH, Bouko Y, Samson D, et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol. 2004;126(5):665-674. (Pubitemid 39221301)
41. Puig N, Sarasquete ME, Alcoceba M, et al. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Ann Hematol. 2013;92(1): 97-100.
42. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia. 2003;17(6): 1013-1034. (Pubitemid 36722231)
43. San-Miguel JF, Paiva B, Gutierrez NC. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book. 2013;33.e313.
44. Frébet E, Abraham J, Geneviève F, et al; GEIL Groupe d'Etude Immunologique des Leucémies Study Group. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma. Cytometry B Clin Cytom. 2011;80(3):176-185.
45. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood. 2013;122(6):1088-1089.
46. Rawstron AC, Orfao A, Beksac M, et al; European Myeloma Network. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93(3):431-438. (Pubitemid 351398645)
47. Zamagni E, Nanni C, Pezzi A, et al. PET/CT is a useful tool for both refining the definition of complete response in multiple myeloma and detecting otherwise unrevealed progression during the follow-up of the disease: a single centre experience on 282 patients ASH Annual Meeting Abstracts. Blood. 2013;122:1936. [ASH Annual Meeting Abstracts].
48. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 2008;68(1):190-197. (Pubitemid 351380120)
49. Reghunathan R, Bi C, Liu SC, et al. Clonogenic multiple myeloma cells have shared stemness signature assocuated with patient survival. Oncotarget. 2013;4(8):1230-1240.
50. Paiva B, Paino T, Sayagues JM, et al. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile. Blood. 2013; 122(22):3591-3598.